ArticleCurrent infectious disease reports2011
Community-Acquired Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections: Management and Prevention.
Article in Current infectious disease reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intrawound vancomycin in primary hip and knee arthroplasty: a safe and cost-effective means to decrease early periprosthetic joint infection.Arthroplasty today · 2018Article
- Oral Antimicrobial Therapy: Efficacy and Safety for Methicillin-Resistant Staphylococcus aureus Infections and Its Impact on the Length of Hospital Stay.Infection & chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) was a rare phenomenon until the past decade; now CA-MRSA is endemic in many communities and is the most common cause of skin and soft tissue infections presenting to emergency rooms. CA-MRSA is distinct from its hospital-acquired counterpart, and has caused devastating infections in many healthy individuals. The epidemiology of CA-MRSA continues to evolve, and the challenge is to use the most appropriate and effective therapeutic and preventative strategies against this pathogen. This article reviews the current epidemiology of CA-MRSA, its definitions, and common clinical manifestations in the community. The article also summarizes current therapeutic options for CA-MRSA as well as strategies to reduce the transmission and the impact of CA-MRSA in both community and health care settings.
Identifiers
21773687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.